Literature DB >> 26221384

The association between NFKB1-94ins/del ATTG polymorphism and non-small cell lung cancer risk in a Chinese Han population.

Yue Wang1, Libo Chen2, Liming Pan3, Jinru Xue1, Haixiang Yu1.   

Abstract

This study aimed to clarify the influence of a common insertion/deletion polymorphism (-94ins/del ATTG, rs28362491) in the Nuclear factor-κB1 (NFKB1) promoter on non-small cell lung cancer (NSCLC) susceptibility. We genotyped the NFKB1 -94ins/del ATTG polymorphism by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method and assessed the association with NSCLC risk, clinicopathological parameters in a case-control study of 421 cases and 425 controls. Heterozygous (ID) genotype disclosed a statistically significantly increased risk of developing NSCLC (OR = 1.57, 95% CI 1.13-2.19, P = 0.007). Homozygous (II) genotype also showed an increased risk of NSCLC (OR = 1.87, 95% CI 1.27-2.75, P = 0.001). Statistically significant difference was observed when the patients and controls were compared according to ID + II versus DD (OR = 2.01, 95% CI 1.47-2.76, P<0.001). The I allele was significantly higher in the NSCLC cases compared to the controls (52.9% versus 45.1%). The I allele was significantly associated with NSCLC risk (OR = 1.37, 95% CI 1.12-1.65, P = 0.001). There was a significantly higher frequency of ID + II genotypes observed in smokers, compared to non-smokers (OR = 1.99, 95% CI 1.22-3.24, P = 0.005) and in patients with stage III + IV, compared to stage I + II (OR = 2.16, 95% CI 1.34-3.49, P = 0.002). This study suggested that NFKB1 -94ins/del ATTG polymorphism was significantly associated with NSCLC risk in Chinese Han population.

Entities:  

Keywords:  Non-small cell lung cancer; genetics; nuclear factor-κB; polymorphism

Year:  2015        PMID: 26221384      PMCID: PMC4509329     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  13 in total

1.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

2.  Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy.

Authors:  Tolia G Maria; Kouloulias E Vasileios; Pantelakos S Panagiotis; Syrigos N Kostas
Journal:  Int J Clin Exp Med       Date:  2012-11-18

3.  Dermatomyositis as an early manifestation and a significant clinical precursor of lung cancer: report of a rare case and review of the current literature.

Authors:  Tsoukalas Nikolaos; Tolia Maria; Kostakis D Ioannis; Lypas Georgios; Pistamaltzian Nikolaos; Demiri Stamatina; Panopoulos Christos; Koumakis Georgios; Barbounis Vasileios; Efremidis Anna
Journal:  Int J Clin Exp Med       Date:  2013-01-26

Review 4.  The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target.

Authors:  Yonghui Yu; Yu Wan; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

Review 5.  Lung cancer screening.

Authors:  U Pastorino
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

6.  NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Raquel López-Mejías; Mercedes García-Bermúdez; Carlos González-Juanatey; Santos Castañeda; José A Miranda-Filloy; Carmen Gómez-Vaquero; Benjamín Fernández-Gutiérrez; Alejandro Balsa; Dora Pascual-Salcedo; Ricardo Blanco; Isidoro González-Álvaro; Javier Llorca; Javier Martín; Miguel A González-Gay
Journal:  Atherosclerosis       Date:  2012-06-13       Impact factor: 5.162

7.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

Review 8.  NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases.

Authors:  X-F Sun; H Zhang
Journal:  Histol Histopathol       Date:  2007-12       Impact factor: 2.303

9.  Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma.

Authors:  T Mukhopadhyay; J A Roth; S A Maxwell
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

10.  NFκB1 and NFκBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population.

Authors:  Shunxin Song; Dianke Chen; Jiachun Lu; Jiawei Liao; Yanxin Luo; Zuli Yang; Xinhui Fu; Xinjuan Fan; Yisheng Wei; Lei Yang; Lei Wang; Jianping Wang
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

View more
  6 in total

1.  Biological interaction of cigarette smoking on the association between genetic polymorphisms involved in inflammation and the risk of lung cancer: A case-control study in Japan.

Authors:  Yuzo Yamamoto; Chikako Kiyohara; Saiko Suetsugu-Ogata; Naoki Hamada; Yoichi Nakanishi
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

2.  Association and interaction of NFKB1 rs28362491 insertion/deletion ATTG polymorphism and PPP1R13L and CD3EAP related to lung cancer risk in a Chinese population.

Authors:  Jiaoyang Yin; Huiwen Wang; Ulla Vogel; Chunhong Wang; Wei Hou; Yegang Ma
Journal:  Tumour Biol       Date:  2015-11-13

Review 3.  An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility.

Authors:  Yi-Qiao Luo; Duan Wang; Teng Gong; Jiang Zhu
Journal:  Oncotarget       Date:  2016-09-06

Review 4.  NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.

Authors:  Wen Fu; Zhen-Jian Zhuo; Yung-Chang Chen; Jinhong Zhu; Zhang Zhao; Wei Jia; Jin-Hua Hu; Kai Fu; Shi-Bo Zhu; Jing He; Guo-Chang Liu
Journal:  Oncotarget       Date:  2017-02-07

5.  Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies.

Authors:  Duan Wang; Tianhang Xie; Jin Xu; Haoyang Wang; Weinan Zeng; Shuquan Rao; Kai Zhou; Fuxing Pei; Zongke Zhou
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

6.  miR-135a inhibits malignant proliferation and diffusion of non-small cell lung cancer cells by down-regulating ROCK1 protein.

Authors:  Yanan Zhao; Xiaosong Sun; Kun Zhu; Min Cheng
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.